Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The venue will be the Fairmont Copley Plaza in Boston.

Please contact Julie Powers Julie@worldhealthcommunications.com with your interest in attending this exciting program as space is limited.

iwMyeloma 2016

22–24 April 2016 | Fairmont Copley Plaza, Boston

iwMyeloma 2016

22–24 April 2016 | Fairmont Copley Plaza, Boston

The venue will be the Fairmont Copley Plaza in Boston.

Please contact Julie Powers Julie@worldhealthcommunications.com with your interest in attending this exciting program as space is limited.

Myeloma 2016: Panel discussion on the new treatment paradigm 11:57
Myeloma 2016: Panel discussion on the new treatment paradigm
Gareth Morgan et al.
Myeloma 2016: Panel discussion on novel treatments 13:09
Myeloma 2016: Panel discussion on novel treatments
Keith Stewart et al. • 22 Apr 2016
Mechanism of action of daratumumab 2:03
Mechanism of action of daratumumab
Niels van de Donk • 22 Apr 2016
LCL161 – a new approach to treating multiple myeloma 4:42
LCL161 – a new approach to treating multiple myeloma
Marta Chesi • 22 Apr 2016
Update on trametinib for multiple myeloma 2:14
Update on trametinib for multiple myeloma
Faith Davies • 22 Apr 2016
Perspectives on future paths to cure multiple myeloma 1:36
Perspectives on future paths to cure multiple myeloma
Antonio Palumbo • 22 Apr 2016
The importance of the microenvironment in multiple myeloma 1:08
The importance of the microenvironment in multiple myeloma
Faith Davies • 22 Apr 2016
Clinical management of venetoclax in multiple myeloma 1:28
Clinical management of venetoclax in multiple myeloma
Lawrence Boise • 22 Apr 2016
The biology of the plasma cell and drug targets in multiple myeloma 1:07
The biology of the plasma cell and drug targets in multiple myeloma
Lawrence Boise • 22 Apr 2016
Tolerability of monoclonal antibodies in multiple myeloma 1:13
Tolerability of monoclonal antibodies in multiple myeloma
Thomas Martin • 22 Apr 2016
Isatuximab for multiple myeloma – promising results and next steps 2:20
Isatuximab for multiple myeloma – promising results and next steps
Thomas Martin • 22 Apr 2016
MMRF presents highlights for patients at Myeloma 2016 5:17
MMRF presents highlights for patients at Myeloma 2016
Daniel Auclair et al. • 22 Apr 2016
PET-CT vs MRI in multiple myeloma 1:59
PET-CT vs MRI in multiple myeloma
Philippe Moreau • 22 Apr 2016
How immunomodulatory drugs have reinforced the value of the immune system in multiple myeloma 3:06
How immunomodulatory drugs have reinforced the value of the immune system in multiple myeloma
Jesús San Miguel • 22 Apr 2016
Results of KEYNOTE-023 and pembrolizumab plus pomalidomide trials for multiple myeloma 3:49
Results of KEYNOTE-023 and pembrolizumab plus pomalidomide trials for multiple myeloma
Jesús San Miguel • 22 Apr 2016
Venetoclax for multiple myeloma – mechanism of action and next steps 1:58
Venetoclax for multiple myeloma – mechanism of action and next steps
Lawrence Boise • 22 Apr 2016
The content of VJHemOnc is intended for healthcare professionals